Biocytogen
Biocytogen has developed its proprietary RenMice® platforms—including RenMab®, RenLite®, RenNano®, RenTCR™, and RenTCR mimic™—to enable the discovery of fully human monoclonal, bispecific, and multispecific antibodies, bispecific ADCs, hu-VHH antibodies, and TCR mimic antibodies. Through its RenSuper™ Biologics initiative, the company offers an off-the-shelf library of over one million fully human antibody sequences against more than 1,000 targets for global collaboration. In addition, its BioMice™ brand provides thousands of gene-edited animal and cell models, along with preclinical pharmacology and gene-editing services, supporting drug discovery programs worldwide.
